Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 341 results found since Jan 2013.
Fight Aging! Newsletter, February 7th 2022
In this study, we used accelerometer measurements (1) to examine the association of physical activity and mortality in a population-based sample of US adults and (2) to estimate the number of deaths prevented annually with modest increases in moderate-to-vigorous physical activity (MVPA) intensity.
This analysis included 4,840 participants. Increasing MVPA by 10, 20, or 30 minutes per day was associated with a 6.9%, 13.0%, and 16.9% decrease in the number of deaths per year, respectively. We estimated that approximately 110,000 deaths per year could be prevented if US adults aged 40 to 85 years or older increased th...
Source: Fight Aging! - February 6, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Roger Chou ’s Undisclosed Conflicts of Interest: How the CDC’s 2016 Guideline for Prescribing Opioids for Chronic Pain Lost Its Clinical and Professional Integrity
by Chad D. Kollas MD, Terri A. Lewis PhD, Beverly Schechtman and Carrie Judy“I ' m present. Uh … I do have a conflict. I receive funding to conduct reviews on opioids, and I ' ll be recusing myself after the um, director ' s, uh, um, um, uh … update.”- Dr. Roger Chou, Center for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) Board of Scientific Counselors (BSC) Meeting Friday, July 16, 2021.IntroductionFor those familiar with the controversial relationship between the anti-opioid advocacy group, Physicians for Responsible Opioid Prescribing (PROP, recently renamed, He...
Source: Pallimed: A Hospice and Palliative Medicine Blog - September 17, 2021 Category: Palliative Care Tags: CDC judy kollas lewis opioid pain schechtman Source Type: blogs
Roger Chou s Undisclosed Conflicts of Interest: How the CDCs 2016 Guideline for Prescribing Opioids for Chronic Pain Lost Its Clinical and Professional Integrity
by Chad D. Kollas MD, Terri A. Lewis PhD, Beverly Schechtman and Carrie JudyI ' m present. Uh I do have a conflict. I receive funding to conduct reviews on opioids, and I ' ll be recusing myself after the um, director ' s, uh, um, um, uh update.- Dr. Roger Chou, Center for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) Board of Scientific Counselors (BSC) Meeting Friday, July 16, 2021.IntroductionFor those familiar with the controversial relationship between the anti-opioid advocacy group, Physicians for Responsible Opioid Prescribing (PROP, recently renamed, Health Pro...
Source: Pallimed: A Hospice and Palliative Medicine Blog - September 17, 2021 Category: Palliative Care Tags: CDC judy kollas lewis opioid pain schechtman Source Type: blogs
If FDA Won ’t Rethink Rules on Off‐Label Drug Use, Courts Should
Walter OlsonAs Cato writershave longpointedout, the law takes a paradoxical stance toward so ‐called “off‐label” use of drugs approved for use by the Food and Drug Administration (FDA). On the one hand, it’s completely lawful for physicians to prescribe approved drugs for other than the FDA‐approved uses, and such uses are vital in everyday practice. Indeed, off‐la bel compounds oftenconstitute a “gold standard” of care in chemotherapy cancer treatments and other fields of medicine. On the other hand, the agency strictly prohibits makers of the compounds frompromoting such use, even when ...
Source: Cato-at-liberty - August 11, 2021 Category: American Health Authors: Walter Olson Source Type: blogs
Anti ‐Vaxxers Turn to Big Government
Thomas A. FireyCOVID-19hospitalizations anddeaths are rising in the United States as the highly infectious Delta variant of the SARS-CoV-2 virus has becomethe dominant strain in the country. These serious cases arealmost entirely limited to people who are not vaccinated against the virus; for the vaccinated,infection rates are much lower and nearly all infections are no more troublesome than a cold or — at worst – a bout of the flu, and often go unnoticed altogether.COVID-19 causedat least11 percent of all U.S. deaths in 2020, making it thethird leading cause of death, behind only heart disease and cancer. So far in 20...
Source: Cato-at-liberty - August 2, 2021 Category: American Health Authors: Thomas A. Firey Source Type: blogs
The explosion of mental health apps raises substantial opportunities –and tough questions
In the eyes of the tech industry, mental health treatment is an area ripe for disruption.
In any given year, 1 in 5 adults in the U.S. experience a form of mental illness, according to federal estimates. And research indicates only about half of them receive treatment in a system that is understaffed and ill distributed to meet demand.
For tech startups looking to cash in on unmet need, that translates into more than 50 million potential customers.
Venture capital firms invested more than $2.4 billion in digital behavioral health apps in 2020 — more than twice the amount invested in 2019 — touting support or treatment ...
Source: SharpBrains - June 28, 2021 Category: Neuroscience Authors: Kaiser Health News Tags: Brain/ Mental Health Technology & Innovation anxiety BetterHelp brain-illness Brightside cerebral depression digital behavioral health FDA Food and Drug Administration Ginger health apps mental illness mental-health-treatment Source Type: blogs
Why “Radiopharmaceutical” Should be Part of your Healthcare Vocabulary
By JAY T. RIPTON
Not to sound too alarmist, but the radiopharmaceutical industry is on the verge of an explosion. But don’t worry; it’s not the type of explosion one often associates with nuclear materials… I love those movies too! It’s the beginning of a new wave of innovation for the diagnosis and treatment of certain cancers and other diseases.
This new radiopharmaceutical boom quite literally has the life sciences industry in a nuclear arms race of sorts, as companies like Y-mAbs, Novartis and others are pushing through clinical trials for the next blockbuster for the treatment and detection of hard-t...
Source: The Health Care Blog - June 14, 2021 Category: Consumer Health News Authors: Christina Liu Tags: Medical Practice jay t ripton nuclear medicine radiation oncology radiopharmaceuticals Source Type: blogs
Fight Aging! Newsletter, May 3rd 2021
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - May 2, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Evaluation of the Surgical Specimen After Neoadjuvant Systemic Therapy
ConclusionPostneoadjuvant systemic therapy histopathological changes are complex, and careful systematic review of the specimen is required for accurate diagnosis and follow-up treatment. For pathological complete response to be used as an indicator of response to novel therapies, it is essential to have a standardized way in which residual disease is measured and reported. We designed the recommendations specifically for the clinical trial setting; however, they can be optionally incorporated into routine practice because, in our opinion, standardization is most effective when uniformly applied. Hopefully, such standardiz...
Source: Oncopathology - March 23, 2021 Category: Cancer & Oncology Tags: breast Breast Biopsy Procedure breast cancer Source Type: blogs
Fight Aging! Newsletter, March 22nd 2021
This article expresses sentiments regarding medical technology and human longevity that we'd all like to see more of in the mainstream media. At some point, it will come to be seen by the average person as basically sensible to work towards minimizing the tide of suffering and death caused aging and age-related disease. It has been, in hindsight, a strange thing to live in a world in which most people were reflexively opposed to that goal.
Death and aging constitute a mystery. Some of us die more quickly. We often ask about it as children, deny it in youth, and reluctantly come to accept it as adults. Aging is uni...
Source: Fight Aging! - March 21, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The Popular Science Media Fails to Distinguish Between Potentially High Yield and Probably Low Yield Treatments for Aging
It is of great importance to distinguish, where we can, between promising and poor approaches to the treatment of aging. If only poor approaches are developed, then we'll age, suffer, and die on much the same schedule as our grandparents. In the article here, metformin and senolytics are crammed together side by side, as though the same thing. They are very much not the same thing.
Metformin is almost certainly a poor approach to the treatment of aging. The animal data is terrible, while the human data shows only a modest effect size. Senolytics are most likely a promising approach. The animal data is amazing: robus...
Source: Fight Aging! - March 16, 2021 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, February 8th 2021
This study was divided in two phases: CALERIE-1 and CALERIE-2. CALERIE-1 study was performed to assess the possible effects induced by a reduction of 10-30% of caloric intake on body composition parameters and lipid profile after 6 and 12 months in a population of middle-aged non-obese subjects. CALERIE-1 results showed an improvement in lipid and glycemic profile and a reduction in body weight (BW) and fat mass.
CALERIE-2 was the largest multi-center study on CRD. A total of 220 subjects were enrolled randomly with a 2:1 allocation into two subgroups: 145 in the CRD group and 75 in the ad libitum group. The CRD gro...
Source: Fight Aging! - February 7, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, January 11th 2021
This study demonstrates the potential of a natural (o-Vanillin) and a synthetic (RG-7112) senolytic compounds to remove senescent IVD cells, decrease SASP factors release, reduce the inflammatory environment and enhance the IVD matrix production. Removal of senescent cells, using senolytics drugs, could lead to improved therapeutic interventions and ultimately decrease pain and a provide a better quality of life of patients living with intervertebral disc degeneration and low back pain.
From Ying Ann Chiao of Oklahoma Medical Research Foundation: Mitochondrial dysfunction plays a central role in aging and cardiovasc...
Source: Fight Aging! - January 10, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The Great Bucatini Shortage of 2020 and the FDA ’s History of Telling Italians How to Make Italian Food
Michael F. CannonRachel Handler has a delightfulpiece atNew Yorkmagazine ’s food and restaurant blogGrub Street on how Big Pasta is using government regulation to punish competitors and consumers. The result is that the U.S. Food and Drug Administration, in addition to causing a shortage of COVID-19diagnostic tests andvaccines, is basically causing a nationwide shortage of bucatini.On March 30, at the beginning of a pandemic whose supply shocks were making everything from toilet paper to pasta harder to get, the FDAblocked imports of De Cecco bucatini. The FDA found the iron content of the Italian company’s bu...
Source: Cato-at-liberty - December 30, 2020 Category: American Health Authors: Michael F. Cannon Source Type: blogs
